0000000000778762

AUTHOR

Marianna Alacqua

showing 2 related works from this author

Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

2006

Aims To compare information on drug–drug interactions (DDIs) reported on two standard drug-related information sources (Summary of Product Characteristics and Drugdex system by Micromedex), by assessing the prevalence and predictors of potential DDI with proton pump inhibitors (PPIs) in general practice. Methods From the ‘Caserta-1’ Local Health-Service database, 156 general practitioners (GPs) were recruited. From more than 180 000 individuals registered on their lists, we selected patients receiving co-prescription of PPI and medications at interaction risk, according to the Italian Summary of Product Characteristics (SPC) of PPI and Drugdex information, during the year 2003. Thereafter, …

DrugAdultMalemedicine.medical_specialtyAdolescentmedia_common.quotation_subjectPharmacology toxicologyToxicologyDrugdexDrug PrescriptionsInternal medicineEpidemiologymedicineHumansPharmacology (medical)Drug InteractionsSummary of Product CharacteristicsRisk factorMedical prescriptiondrug information sourcesSummary of Product Characteristicsmedia_commonAgedgeneral practicePharmacologyAged 80 and overObserver VariationDrug pairbusiness.industryPharmacoepidemiologydrug information sources Drugdex drug–drug interaction general practice proton pump inhibitors Summary of Product CharacteristicsRegression analysisProton Pump InhibitorsDrug interactionMiddle Ageddrug information sources; Drugdex; drug-drug interaction; general practice; proton pump inhibitors; Summary of Product CharacteristicsSpontaneous reportingFamily medicineDrug Information ServicesInformation sourceFemalebusinessFamily Practicedrug-drug interactionBritish journal of clinical pharmacology
researchProduct

Eosinophilic and Noneosinophilic Asthma

2021

Background Phenotypic characteristics of patients with eosinophilic and noneosinophilic asthma are not well characterized in global, real-life severe asthma cohorts. Research Question What is the prevalence of eosinophilic and noneosinophilic phenotypes in the population with severe asthma, and can these phenotypes be differentiated by clinical and biomarker variables? Study Design and Methods This was an historical registry study. Adult patients with severe asthma and available blood eosinophil count (BEC) from 11 countries enrolled in the International Severe Asthma Registry (January 1, 2015-September 30, 2019) were categorized according to likelihood of eosinophilic phenotype using a pre…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationCritical Care and Intensive Care Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineEosinophilicmedicine030212 general & internal medicineeducationAsthmaeducation.field_of_studybusiness.industryEosinophilmedicine.diseaseBenralizumab3. Good healthmedicine.anatomical_structure030228 respiratory systemchemistryExhaled nitric oxideCohortBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessChest
researchProduct